AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy (NANOCOL)

  • End date
    May 19, 2024
  • participants needed
  • sponsor
    Gustave Roussy, Cancer Campus, Grand Paris
Updated on 5 March 2022
coronary artery disease
absolute neutrophil count
external beam radiotherapy


This is a phase 1 clinical trial evaluating the safety, tolerability of escalating doses of AGuIX-NP in combination with radiation and cisplatin in patients with locally advanced cervical cancer. Dose escalation will be conducted using the modified toxicity probability interval (mTPI) method.

Three dose levels of intravenous AGuIX nanoparticles will be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2).

Condition Gynecologic Cancer
Treatment External Beam Radiotherapy (EBRT), Chemotherapy (Cisplatin), Polysiloxane Gd-Chelates based nanoparticles (AGuIX), Uterovaginal brachytherapy
Clinical Study IdentifierNCT03308604
SponsorGustave Roussy, Cancer Campus, Grand Paris
Last Modified on5 March 2022


Yes No Not Sure

Inclusion Criteria

Patients with histologically confirmed cancer of the uterine cervix: squamous cell carcinoma or adenocarcinoma stage IB2-IVA according to the International Federation of Gynecology and Obstetrics classification, regardless of the pelvic lymph node stage. No evidence of metastatic disease. Primary staging should include: clinical examination, Pelvic MRI and 18-FDG PET. A coelioscopic para-aortic lymph node staging should be done in patients without para-aortic lymph node uptake to guide radiotherapy fields in the situation of pelvic lymph node metastases. If there is no pelvic lymph node metastases, para-aortic lymph node dissection is optional
ECOG performance status 0-1
Age between 18 - 70 years
Neutrophils > 2000/mm^3
Hemoglobin > 9 g/L after transfusion if necessary
Platelets > 100,000/mm^3
Creatinine < 1.5 upper limit of normal or calculated creatinine clearance (Cockcroft-Gault Formula) 60 mL/min
Liver function (GOT, GPT, alkaline phosphatase and bilirubin) < 1.5 upper limit of normal
Cardiovascular: no clinically relevant cardiovascular disease, no congestive heart failure, no symptomatic coronary artery disease, no poorly controlled cardiac arrhythmia, no myocardial infarction within the past year
Gastrointestinal: no active inflammatory bowel disease, no lack of physical integrity of the upper gastrointestinal tract, no malabsorption syndrome
Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to initiation of treatment
Proteinuria < 2 g/L (200mg/dL) and creatinine clearance 60 mL/min
Signed informed consent after informing the patient
Patient affiliated to a social security regimen or beneficiary of the same

Exclusion Criteria

Other histological types of cervical cancer than those listed in the inclusion criteria or stage IVB
History of cancer other than basal cell carcinoma within five past years
Prior treatment with radiotherapy, chemotherapy, targeted therapy or immune therapy for cervical cancer or for any cancer within five past years
Prior pelvic radiotherapy or prior surgical treatment for cervical cancer (excluding diagnostic conisation)
Pregnancy or breastfeeding
Obesity (Body Mass Index > 30)
History of prior or current psychiatric illness
Nephropathy, regardless of the grade
Peripheral neuropathy grade 2
Patients with pre-existing hearing impairments
Active infection or other serious underlying pathology that could prevent the patient from receiving the treatment (especially liver or heart conditions)
Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Inclusion in another clinical trial protocol with an experimental molecule (during this study or within 5 years prior to enrollment)
Unable to undergo the follow-up required by study for geographical, social or psychological reasons
Contra-indication for Magnetic Resonance Imaging enhanced with gadolinium and/or any contra-indication to the use of cisplatin
History of allergic reaction to cisplatin or other platinum containing compounds
Concurrent administration of yellow fever vaccine
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note